What “Insurmountable” Means in a Functional Assay
A concentration-response curve can change in more than one way when an antagonist is present. It may shift to the right, so that more agonist is needed to produce a given response, while retaining the same maximum. Alternatively, the response may approach a lower maximum even at high agonist concentrations. The first pattern is compatible with surmountable competitive antagonism under equilibrium conditions. The second is described functionally as insurmountable antagonism.
“Insurmountable” describes the observed concentration-response pattern, not a unique molecular mechanism. The term means that, over the tested conditions and concentration range, increasing agonist concentration does not restore the control maximum. A reduced maximum can have several explanations, and a finite assay range or inadequate equilibration can make the pattern misleading.
For a fixed antagonist condition, a common empirical model is
Here \(A\) is agonist concentration, \(E_0\) is the baseline response, \(E_{\max}\) is the asymptotic response for that condition, \(EC_{50}\) is the agonist concentration producing half of the response range from \(E_0\) to \(E_{\max}\), and \(n_H\) is the Hill slope. The parameters may differ across antagonist conditions; in particular, compare fitted \(E_{\max}\) values rather than relying on responses at a single agonist concentration. The \(EC_{50}\) is a functional potency measure in that assay, not by itself a measure of binding affinity.
Why Simple Competitive Antagonism Preserves the Maximum
The contrast with simple competitive antagonism follows from an equilibrium, one-site binding model. Assume agonist \(A\) and a reversible neutral antagonist \(B\) bind mutually exclusively to the same receptor site; free concentrations are constant during the measurement; binding has reached equilibrium; and the response depends on agonist occupancy through the same relationship with and without antagonist. These assumptions are restrictive, but they clarify what a parallel rightward shift predicts.
Let \(K_A\) and \(K_B\) be the equilibrium dissociation constants for agonist and antagonist, respectively. Under these assumptions, the fraction of receptors occupied by agonist is
At a fixed \(B\), the antagonist therefore increases the agonist concentration needed to attain a given occupancy. But as agonist concentration increases without bound,
Thus, under the stated assumptions, sufficiently high agonist concentration displaces the reversible competitive antagonist and restores full agonist occupancy. If response is governed by the same occupancy-response relationship in both conditions, the asymptotic response is also unchanged. A rightward shift alone is therefore not evidence of a reduced maximum.
This reasoning does not say that every antagonist must preserve the maximum. It says that a reduced maximum is inconsistent with the simple equilibrium competitive model as specified. Departures from its assumptions, or other pharmacological processes, can change the pattern. The functional curve indicates what happened in the assay; additional evidence is needed to identify why.
Reading the Curve: Maximum, Potency, and Plateau
Estimate the response at baseline and at the upper end of the agonist range for each antagonist condition. Then ask whether the upper responses form a plateau and whether the plateau levels differ. A well-supported reduction in \(E_{\max}\) is more informative than a difference in response at one concentration. If the curve is still rising at the highest tested concentration, the data do not establish its asymptote.
For a fair comparison, use matched assay conditions, including the same tissue or cell preparation, response scale, incubation and measurement procedures, and agonist exposure protocol. The antagonist condition should be defined clearly, including its concentration and pretreatment. The concentration range should cover the rising part of the curve and enough of its upper region to distinguish a plateau from continued increase. Replication is needed to assess variability; a small apparent difference between fitted maxima may be uncertain.
Worked Example: A Rightward Shift With the Same Maximum
Suppose a hypothetical assay has \(E_0=5\) response units, \(E_{\max}=105\) response units, and Hill slope \(n_H=1\) without antagonist. Its agonist \(EC_{50}\) is \(10\) nM. At a fixed antagonist concentration, the measured curve is consistent with a tenfold rightward shift: \(EC_{50}=100\) nM, with the same fitted \(E_{\max}=105\) response units.
At \(A=1{,}000\) nM, the no-antagonist prediction is
For the antagonist condition, the prediction at the same agonist concentration is
The responses differ at \(1{,}000\) nM, but the fitted asymptotes are both \(105\) response units. In this example, the concentration-specific difference reflects a rightward shift, not insurmountable antagonism. The conclusion depends on the curves actually supporting a common plateau, rather than merely assigning the same maximum in a fit.
Worked Example: A Lower Plateau in the Antagonist Condition
Consider hypothetical curves with a common baseline of \(4\) response units and Hill slope \(n_H=1\). Without antagonist, the fitted \(E_{\max}\) is \(104\) response units and \(EC_{50}=10\) nM. With a fixed antagonist concentration, the fitted \(E_{\max}\) is \(64\) response units and \(EC_{50}=30\) nM. Assume observations at high agonist concentrations are consistent with plateaus under both conditions.
At \(A=1{,}000\) nM, the control prediction is
For the antagonist condition at the same concentration,
At \(A=3{,}000\) nM, the antagonist-condition prediction is
which is close to its fitted asymptote of \(64\) response units. The fitted response range above baseline is \(64-4=60\) response units, compared with \(104-4=100\) response units in control. The antagonist-condition maximum is therefore 60% of the control maximum above baseline. Given the stated plateau evidence, this pattern supports a functional description of insurmountable antagonism under these assay conditions. It does not, by itself, identify the mechanism producing the lower maximum.
Checks, Alternatives, and Limits of Interpretation
A principal failure mode is confusing an unobserved asymptote with a genuinely reduced asymptote. For example, with \(n_H=1\), \(E_0=0\), and a true maximum of \(100\) response units, a curve with \(EC_{50}=100\) nM gives
If the assay tests only up to \(30\) nM, the observed response may look far below the control maximum. Yet the same curve approaches \(100\) response units at higher concentrations. Without an adequate range, the lower observed response cannot distinguish a shifted curve from a lower asymptote.
Other diagnostics matter as well. Inspect replicate data and uncertainty in the fitted maxima; examine whether the highest concentrations actually level off; and check that the response measurement remains reliable at those concentrations. Confirm that the antagonist condition and pretreatment are consistent and that the assay has had enough time to approach the intended equilibrium. If equilibration is incomplete, a pattern that appears insurmountable may depend on the timing of measurement. Solubility, nonspecific effects, loss of tissue responsiveness, or an assay ceiling can also distort the upper portion of a curve.
The main alternative pattern is surmountable competitive antagonism: under the equilibrium assumptions above, the agonist curve shifts right while retaining its asymptotic maximum. The introductory material on Schild regression relates concentration ratios from such shifts to antagonist affinity under its assumptions. A lowered maximum does not fit that simple pattern, but it does not automatically establish a particular alternative mechanism. Distinguishing mechanisms requires appropriate additional evidence, not just a visual label applied to one functional curve.
As a practical comparison, a shared-maximum fit and a separate-maximum fit can be used to summarize the competing curve patterns. The shared-maximum model constrains \(E_{\max}\) across conditions while allowing potency to differ; the separate-maximum model allows both potency and maximum to differ. These are model comparisons, not mechanistic tests. The conclusion should reflect uncertainty, data coverage, and model adequacy. If the tested concentrations do not define a plateau, the separate maximum can be poorly determined and apparent model preference may be driven by extrapolation.
Insurmountability is consequently conditional on the agonist, antagonist concentration, assay system, exposure schedule, and response endpoint. Different tissues or assay designs can yield different functional maxima. A lower fitted \(E_{\max}\) is an important observation, but alone it neither proves that the antagonist is noncompetitive nor establishes a molecular cause.
Worked Example: Distinguishing a Low Observation From a Low Maximum
Suppose a hypothetical control curve has \(E_0=0\), \(E_{\max}=100\) response units, \(EC_{50}=1\) nM, and \(n_H=1\). An antagonist-condition curve is suspected to be a competitive right shift with \(EC_{50}=100\) nM, but the assay’s highest agonist concentration is \(30\) nM. Calculate and compare the responses at that concentration.
The control response is
The shifted-curve response is
The antagonist-condition response is much lower at the assay limit. But the model’s asymptote is \(100\) response units in both conditions. At \(10{,}000\) nM, the shifted curve predicts \(100(10{,}000)/(100+10{,}000)\approx99.01\) response units. Thus, these data through \(30\) nM cannot demonstrate a reduced maximum; they are compatible with a right shift whose plateau has not been observed.
Confirm that control and antagonist curves use comparable conditions and a clearly specified antagonist exposure.
Determine whether both curves approach plateaus; if not, treat the maximum comparison as unresolved.
Distinguish a change in \(EC_{50}\) from a change in \(E_{\max}\), and consider uncertainty in both estimates.
Describe the observed curve pattern as surmountable or functionally insurmountable; do not infer a unique mechanism from the maximum alone.
Check Your Understanding
Answer each question, then compare your reasoning with the solutions.
- Under simple reversible competitive equilibrium, what happens to agonist occupancy as agonist concentration tends to infinity at a fixed antagonist concentration?
- A curve’s response at the highest tested agonist concentration is lower with antagonist, but the curve is still rising. What can you conclude about its maximum?
- In a matched assay, the antagonist condition has a supported plateau 30 response units below the control plateau. What functional description is appropriate, and what does this observation not establish?
- Why is a difference in \(EC_{50}\) not equivalent to a difference in binding affinity?
Solutions. (1) The agonist occupancy tends to 1: \(\lim_{A\to\infty}A/[A+K_A(1+B/K_B)]=1\). Under the model’s shared occupancy-response assumption, the control maximum is therefore recoverable. (2) The asymptote is not established. A right-shifted curve may still rise toward the control maximum, so the data do not yet demonstrate insurmountability. (3) The pattern supports functional insurmountability under the tested conditions, provided the plateau estimates and assay comparison are reliable. It does not by itself identify the antagonist’s molecular mechanism. (4) \(EC_{50}\) is the concentration producing half the measured response range in a specified functional system. It can depend on the assay and response process, so it is not by itself a binding-affinity constant.